Valneva SE - ESG Rating & Company Profile powered by AI
This page is a free Sustainability report covering Valneva SE. Browse to the bottom of the page for potential risks for Valneva SE based on industry, location and size. This analysis of Valneva SE was assembled by All Street Sevva using leading Cognitive Robots.
Valneva SE in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Valneva SE | 8.0 | High |
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Valneva SE have an accelerator or VC vehicle to help deliver innovation?
Does Valneva SE disclose current and historical energy intensity?
Does Valneva SE report the average age of the workforce?
Does Valneva SE reference operational or capital allocation in relation to climate change?
Does Valneva SE disclose its ethnicity pay gap?
Does Valneva SE disclose cybersecurity risks?
Does Valneva SE offer flexible work?
Does Valneva SE have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Valneva SE disclose the number of employees in R&D functions?
Does Valneva SE conduct supply chain audits?
Does Valneva SE disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Valneva SE conduct 360 degree staff reviews?
Does Valneva SE disclose the individual responsible for D&I?
Does Valneva SE disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Valneva SE disclose current and / or historical scope 2 emissions?
Does Valneva SE disclose water use targets?
Does Valneva SE have careers partnerships with academic institutions?
Did Valneva SE have a product recall in the last two years?
Does Valneva SE disclose incidents of discrimination?
Does Valneva SE allow for Work Councils/Collective Agreements to be formed?
Has Valneva SE issued a profit warning in the past 24 months?
Does Valneva SE disclose parental leave metrics?
Does Valneva SE disclose climate scenario or pathway analysis?
Does Valneva SE disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Valneva SE disclose the pay ratio of women to men?
Does Valneva SE support suppliers with sustainability related research and development?
Does Valneva SE disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Valneva SE reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Valneva SE involved in embryonic stem cell research?
Does Valneva SE disclose GHG and Air Emissions intensity?
Does Valneva SE disclose its waste policy?
Does Valneva SE report according to TCFD requirements?
Does Valneva SE disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Valneva SE disclose energy use targets?
Does Valneva SE disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Valneva SE have a policy relating to cyber security?
Have a different question?
Potential Risks for Valneva SE
These potential risks are based on the size, segment and geographies of the company.
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.